Chemical formula: C₂₅H₃₄O₆ Molecular mass: 430.541 g/mol PubChem compound: 6918670
Picato is indicated for the cutaneous treatment of non-hyperkeratotic, non-hypertrophic actinic keratosis in adults. The mechanism of action of ingenol mebutate for use in actinic keratosis remains to be fully characterised. Results from two clinical studies on biological effects of ingenol mebutate have shown that topical administration induced epidermal necrosis and a profound inflammatory response in both epidermis and the upper dermis of the treated skin, dominated by infiltrating T cells, neutrophils and macrophages.
This medicinal substance has been classified in the anatomical therapeutic chemical (ATC) classification according to its main therapeutic use as follows:
| ATC code | Group title | Classification |
|---|---|---|
| D06BX02 | D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06B Chemotherapeutics for topical use → D06BX Other chemotherapeutics | |
Competent medicine agencies globally have authorized commercialization of this active ingredient according to these medication package inserts (MPIs):
| Title | Information Source | Document Type | |
|---|---|---|---|
| PICATO Gel | European Medicines Agency (EU) | MPI, EU: SmPC |
Ingenol mebutate is an active ingredient of these brands:
United States (US)Brazil (BR)Estonia (EE)Lithuania (LT)Poland (PL)Romania (RO)Note the following: The list of brand names is continuously updated, and thus does not include the total of products circulating worldwide. |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.
